CU20110246A7 - Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos - Google Patents

Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos

Info

Publication number
CU20110246A7
CU20110246A7 CU20110246A CU20110246A CU20110246A7 CU 20110246 A7 CU20110246 A7 CU 20110246A7 CU 20110246 A CU20110246 A CU 20110246A CU 20110246 A CU20110246 A CU 20110246A CU 20110246 A7 CU20110246 A7 CU 20110246A7
Authority
CU
Cuba
Prior art keywords
hydrocodone
benzoic acid
methods
acid
conjugates
Prior art date
Application number
CU20110246A
Other languages
English (en)
Other versions
CU24128B1 (es
Inventor
Bindu Bera
Andrea K Martin
Jaroslaw Kanski
Gouchen Chi
Christal Mickle
Sven Guenther
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110246(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of CU20110246A7 publication Critical patent/CU20110246A7/es
Publication of CU24128B1 publication Critical patent/CU24128B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La tecnología descrita actualmente proporciona composiciones que comprenden ácidos aril carboxílicos químicamente conjugados con hidrocodona (morfinan-6-ona, 4, 5-alfa-epoxi-3-metoxi-17-metil) para formar profármacos/composiciones novedosas de hidrocodona, que incluyen benzoatos y ácidos heteroaril carboxílicos, que tienen un potencial reducido para el abuso de hidrocodona. La presente tecnología también proporciona métodos para tratar pacientes, equipos farmacéuticos y métodos para sintetizar conjugados de la presente tecnología.
CU2011000246A 2009-07-02 2010-07-01 Compuesto de benzoato conjugado a la hidrocodona (bz-hc) CU24128B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22271809P 2009-07-02 2009-07-02
PCT/US2010/040775 WO2011002991A1 (en) 2009-07-02 2010-07-01 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof

Publications (2)

Publication Number Publication Date
CU20110246A7 true CU20110246A7 (es) 2012-04-15
CU24128B1 CU24128B1 (es) 2015-09-29

Family

ID=43411452

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000246A CU24128B1 (es) 2009-07-02 2010-07-01 Compuesto de benzoato conjugado a la hidrocodona (bz-hc)

Country Status (21)

Country Link
US (14) US8461137B2 (es)
EP (2) EP3560336A1 (es)
JP (1) JP5442862B2 (es)
KR (5) KR102038260B1 (es)
CN (1) CN102480959B (es)
AU (1) AU2010266205B2 (es)
BR (1) BR112012000569B8 (es)
CA (1) CA2766388C (es)
CL (1) CL2011003347A1 (es)
CO (1) CO6480991A2 (es)
CR (1) CR20110688A (es)
CU (1) CU24128B1 (es)
IL (2) IL217096A (es)
MX (1) MX2012000128A (es)
MY (1) MY153046A (es)
NZ (1) NZ597235A (es)
RU (1) RU2505541C2 (es)
SG (1) SG177445A1 (es)
UA (1) UA102916C2 (es)
WO (1) WO2011002991A1 (es)
ZA (2) ZA201109438B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2765836C (en) 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
MX362857B (es) * 2011-10-26 2019-02-20 Kempharm Inc Star Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.
KR101454515B1 (ko) * 2012-12-04 2014-10-23 바이오스펙트럼 주식회사 베라트릭 산 또는 이의 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 피부상태 개선용 조성물
US9815844B2 (en) 2013-03-08 2017-11-14 Kempharm, Inc. Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US10395022B2 (en) * 2014-03-07 2019-08-27 British Telecommunications Public Limited Company Access control for a resource
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US9850252B2 (en) 2014-11-25 2017-12-26 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof
EP3226907A1 (en) 2014-12-02 2017-10-11 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
KR20160097867A (ko) * 2015-02-10 2016-08-18 삼성전자주식회사 영상 표시 장치 및 영상 표시 방법
KR101669887B1 (ko) * 2015-03-05 2016-10-28 부산대학교 산학협력단 벤조인산을 유효성분으로 포함하는 임신 촉진용 조성물
US10449190B2 (en) * 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017059459A1 (en) 2015-10-01 2017-04-06 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
KR101800834B1 (ko) 2016-07-20 2017-12-21 중앙대학교 산학협력단 아나카딕산을 유효성분으로 하는 배뇨 장애 예방 및 치료용 조성물
US10406153B2 (en) 2016-08-31 2019-09-10 Noramco, Inc. Process for the preparation of benzhydrocodone hydrochloride
AU2018234911B2 (en) 2017-03-17 2024-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
WO2018191474A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
WO2018191477A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them
US11234975B2 (en) 2017-04-14 2022-02-01 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
WO2019165298A1 (en) 2018-02-23 2019-08-29 Rhodes Technologies Novel opioid compounds and uses thereof
CA3093445A1 (en) 2018-03-08 2019-11-28 Incyte Corporation Aminopyrazine diol compounds as pi3k-.gamma. inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (es)
US1731152A (en) * 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) * 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) * 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
GB2307833B (en) 1995-12-01 2000-06-07 Geco As A data compression method and apparatus for seismic data
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
IL143701A0 (en) * 1999-01-04 2002-04-21 Ml Lab Plc Gene therapy-1
AU3275301A (en) * 2000-01-28 2001-08-07 Rohm And Haas Company Enhanced propertied pharmaceuticals
TWI255186B (en) 2001-06-05 2006-05-21 Control Delivery Sys Inc Sustained-release analgesic compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
CA2477004C (en) * 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
BRPI0414876A (pt) 2003-09-30 2006-11-21 New River Pharmaceuticals Inc compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
CN101023056B (zh) 2004-06-04 2011-05-25 克塞诺波特公司 左旋多巴前药、和组合物及其应用
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
CA2649360A1 (en) 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
CA2653741C (en) * 2006-05-26 2015-07-07 Thomas E. Jenkins Controlled release of phenolic opioids
US20080090771A1 (en) * 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
JP5389656B2 (ja) * 2006-10-20 2014-01-15 マクニール−ピーピーシー・インコーポレーテツド アセトアミノフェン／イブプロフェンの組み合わせおよびこれらの使用方法
WO2009079013A1 (en) * 2007-12-17 2009-06-25 Mallinckrodt Inc. Processes for the production of (+)-'nal' morphinan compounds
CA2765836C (en) 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8623888B2 (en) * 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
MX362857B (es) 2011-10-26 2019-02-20 Kempharm Inc Star Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.
US9850252B2 (en) 2014-11-25 2017-12-26 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof

Also Published As

Publication number Publication date
US20110002990A1 (en) 2011-01-06
BR112012000569B8 (pt) 2021-05-25
KR101795330B1 (ko) 2017-11-07
US20120142719A1 (en) 2012-06-07
EP2448407B1 (en) 2019-09-25
KR20190042115A (ko) 2019-04-23
US9549923B2 (en) 2017-01-24
KR101655972B1 (ko) 2016-09-08
AU2010266205A1 (en) 2012-02-02
KR20170124638A (ko) 2017-11-10
KR101971223B1 (ko) 2019-04-23
ZA201109438B (en) 2013-05-29
US10654863B2 (en) 2020-05-19
JP2012532142A (ja) 2012-12-13
BR112012000569A2 (pt) 2015-09-15
SG177445A1 (en) 2012-02-28
EP2448407A4 (en) 2015-06-03
US20130245265A1 (en) 2013-09-19
US20150065536A1 (en) 2015-03-05
US9132125B2 (en) 2015-09-15
US8461137B2 (en) 2013-06-11
US8748413B2 (en) 2014-06-10
IL259889A (en) 2018-07-31
US20170143696A1 (en) 2017-05-25
CA2766388C (en) 2014-05-27
CA2766388A1 (en) 2011-01-06
BR112012000569B1 (pt) 2021-02-02
CL2011003347A1 (es) 2012-07-13
US8759368B2 (en) 2014-06-24
CR20110688A (es) 2012-03-22
US20130252994A1 (en) 2013-09-26
US8927716B2 (en) 2015-01-06
IL217096A (en) 2015-06-30
KR20160106781A (ko) 2016-09-12
KR20180081176A (ko) 2018-07-13
KR101877467B1 (ko) 2018-07-11
CN102480959A (zh) 2012-05-30
IL217096A0 (en) 2012-02-29
US20150335759A1 (en) 2015-11-26
CU24128B1 (es) 2015-09-29
AU2010266205B2 (en) 2013-08-15
CN102480959B (zh) 2014-05-21
WO2011002991A1 (en) 2011-01-06
UA102916C2 (uk) 2013-08-27
RU2012103476A (ru) 2013-08-10
US10351573B2 (en) 2019-07-16
US20150087667A1 (en) 2015-03-26
US8828978B2 (en) 2014-09-09
NZ597235A (en) 2013-08-30
US20130259909A1 (en) 2013-10-03
MX2012000128A (es) 2012-04-30
US10577376B2 (en) 2020-03-03
KR20120048589A (ko) 2012-05-15
RU2505541C2 (ru) 2014-01-27
JP5442862B2 (ja) 2014-03-12
MY153046A (en) 2014-12-31
US20160193204A1 (en) 2016-07-07
US10358452B2 (en) 2019-07-23
US20180177883A1 (en) 2018-06-28
KR102038260B1 (ko) 2019-10-29
EP2448407A1 (en) 2012-05-09
US20160200731A1 (en) 2016-07-14
US9872915B2 (en) 2018-01-23
US9650387B2 (en) 2017-05-16
US20170226118A1 (en) 2017-08-10
CO6480991A2 (es) 2012-07-16
US20180104352A1 (en) 2018-04-19
ZA201300747B (en) 2014-09-25
EP3560336A1 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
CU20110246A7 (es) Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos
MX362857B (es) Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona
CL2011003094A1 (es) Composicion farmaceutica semi-solida libre de agua que comprende a) un ester del acido 5-aminolevulinico (5-ala) o una sal del mismo, b) uno o mas trigliceridos y c) opcionalmente uno o mas potenciadores de viscosidad; kit farmaceutico; y su uso en el tratamiento fotodinamico del cancer, condiciones pre-cancerosas y no cancerosas asociadas a hpv.
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
IL240673B (en) Synthesis and Composition of Conjugated Amino Acid Binding Groups for Compounds Used for Targeted Imaging of Tumors
UA105229C2 (uk) Фармацевтичний склад
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2011085000A3 (en) Fatty acid derivatives and analogs of drugs
CO2017005203A2 (es) Acido benzoico, derivados de acido benzoico y conjugados de acido carboxilico de heteroarilo de oximorfona, profarmacos, metodos de fabricacion y uso de los mismos
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
MY162934A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
IN2015DN01329A (es)
TH145793A (th) เบนโซอิกแอซิด (Benzoic Acid), อนุพันธ์เบนโซอิกแอซิด และเฮเทอโรเอริลคาร์บอกซิลิกแอซิดคอนจูเกต (Heteroaryl Carboxylic Acid Conjugates) ของไฮโดรโคโดน (Hydrocodone), โพรดรักซ์, วิธีของการผลิตและการใช้ของสารเหล่านี้
CY1115620T1 (el) Νεα μεθοδος συνθεσης ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
CY1117356T1 (el) Νεα μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης της με ενα φαρμακευτικως αποδεκτο οξυ
NZ631461A (en) Novel veterinary pharmaceutical compositions and method for the production thereof
UA112329C2 (uk) Композиція проліків, що містить кон'югат аспірину з гідроморфоном, та спосіб лікування захворювання
TH107166A (th) สารอนุพันธ์อิมิดาโซลิดิโนนในฐานะเป็นสารยับยั้ง 11b-HSD1
TH152683A (th) สารประกอบไตรอะซีนในฐานะตัวยับยั้ง pi3k และ mtor
TH156236A (th) กรดเบนโซอิก, อนุพันธ์ของกรดเบนโซอิก และ เฮเทอโรเอริลคาร์บอกซิลิกแอซิด คอนจูเกตของไฮโดรมอร์โฟน, โพรดรักซ์, วิธีการทำและการใช้สารเหล่านี้ (Benzoic acid, Benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof)
TH110398A (es)

Legal Events

Date Code Title Description
FG Grant of patent